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OBJECTIVES: Rituximab (RTX), is a novel anti-CD20 mono-
clonal antibody that selectively depletes CD20+ B cells, and pro-
vides a new therapeutic option for patients with rheumatoid
arthritis (RA) who have had an inadequate response to anti-
tumour necrosis factor (TNF) inhibitor therapies. This analysis
was conducted to determine the cost-effectiveness of introducing
RTX as an RA therapy option, from the Canadian Ministry of
Health perspective. METHODS: A cost-utility model was devel-
oped to evaluate the direct costs and clinical outcomes of a stan-
dard Canadian treatment sequence in the absence and presence
or RTX + methotrexate (MTX). The model simulated 10,000
RA patients over a life time who have had an inadequate
response to one anti-TNF therapy. Standard Canadian treatment
sequence after failure of the ﬁrst biologic (etanercept) was adal-
imumab + MTX, inﬂiximab + MTX, leﬂunomide, gold,
cyclosporine and palliative care. Baseline characteristics from
REFLEX (Randomized Evaluation of Long-term Efﬁcacy of Rit-
uximab in RA) clinical trial were: 81% female; mean age, 52.2
years; mean HAQ score, 1.88. ACR response rates from RCTs
were placebo-adjusted to minimize bias from cross-trial com-
parisons. All relevant direct costs were included in the model
including drug costs, administration and monitoring, and
adverse events. Observational data were used to estimate long-
term HAQ progression and average time on treatment for
patients responding to therapy. Costs and beneﬁts were dis-
counted at 5% per annum. RESULTS: The introduction of RTX
(to the treatment sequence) following failure of one biologic
resulted in a gain of 0.443 QALYs at an additional total cost of
$8161 over the lifetime of each patient. The incremental cost-
effectiveness ratio (ICER) of RTX was $18,434 per QALY
gained. CONCLUSIONS: Adding RTX to the pool of available
treatment options for Canadian patients with RA who fail to
respond to anti-TNF therapy results in an acceptable incremen-
tal cost per QALY gained.
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OBJECTIVE: Diffusion refers to the process by which new tech-
nologies, i.e. new drugs, devices, procedures and health pro-
grammes, are adopted and disseminated in the health care
system. Early adoption of new technologies in Denmark does not
always seem to be in focus, when compared with the other
Nordic countries. The objective was to identify drivers and bar-
riers inﬂuencing the diffusion in Denmark represented by four
cases: thrombolysis in acute stroke, statins for the prevention of
ischemic heart disease, mammography screening and biological
TNF-alfa drugs in rheumatoid arthritis. METHODS: The overall
method used was the qualitative case-study method, as an empir-
ical inquiry method that investigates a contemporary phenome-
non within its real-life context. The data used were written doc-
umentation (articles, reports, etc.), databases and statistics, and
interview of key opinion leaders and patient organisations. The
diffusion in the four cases was benchmarked with similar status
in Sweden, Norway and Finland. RESULTS: Denmark has in all
four cases been a late adopter, and the level of diffusion is lower
compared with Sweden, Norway and Finland. Except for statins,
the diffusion of the technologies is geographical unequal in
Denmark with the new technologies only offered in some hos-
pitals and counties. Opposed to this for example mammography
screening is fully implemented in Sweden, Norway and Finland.
Professional disagree-ment/uncertainty is one of the identiﬁed
key barriers, where decision-makers demands additional Danish
evi-dence, although international evidence exist. Further key bar-
riers to diffusion are budgetary constraints (e.g. silo mentality),
tradition/culture, and lack of information, knowledge and qual-
iﬁed staff. CONCLUSION: The study has shown that Denmark
is, if not a laggard, then a late adopter with a decentralized health
care system with no concrete policy goals, which makes it further
difﬁcult to disseminate the new technol-ogy in all county coun-
cils. No difference between drugs and other types of technolo-
gies were found.
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Non-selective non-steroidal anti-inﬂammatory drugs (NSAIDs)
have been associated with adverse gastrointestinal (GI) events.
Rofecoxib was introduced as a drug causing fewer GI symptoms
than non-speciﬁc NSAIDs. Merck voluntarily removed it from
the Canadian in September 2004 due to a possible association
with cardiovascular events. No studies have examined the impact
of its removal on utilization of other NSAIDs in Canada.
OBJECTIVES: We examined the utilization (i.e., numbers of
claims) of NSAIDs, proton-pump inhibitors (PPIs) and salicylic
acid derivatives (SADs) in two Canadian provinces one year
prior to and after rofecoxib’s market withdrawal. METHODS:
We obtained monthly drug claims (Oct/03-Nov/05) from Brogan
Inc. We used interrupted time-series design by segmented regres-
sion to examine utilization changes of other coxibs, COX-1
NSAIDs, PPIs and SADs after rofecoxib’s removal. Series were
transformed using ARIMA and other appropriate models to
account for autocorrelation, non-stationarity and heteroscedas-
ticity. RESULTS: All time series were ﬁt with either an ARIMA
or a log linear model. Each model showed excellent ﬁt (R2 =
0.79–0.98). Segmented regression analysis revealed a marked
reduction in total claims for all NSAIDs between September
2004 and January 2005 (−141,524 claims/month; CI95 =
−188,889 to −94,159; p < 0.001). The month-to-month varia-
tion before and after September 2004 was not signiﬁcantly 
different than zero. Monthly coxib claims decreased after rofe-
coxib’s withdrawal (−156,883 claims/month; CI95 = −184,393 to
−129,373; p < 0.001). Non-selective COX-1 inhibitors exhibited
the opposite trend; monthly claims increased 32% to 414,813 at
study end. No shift in utilization of PPIs or SADs was observed.
CONCLUSION: The removal of rofecoxib from the Canadian
market, using two provinces as a proxy, was associated with 
an immediate decrease followed by a slow increase in NSAID
claims. Many patients discontinued NSAIDs, while some
switched to non-selective NSAIDs as an alternative.
